Further analysis of EGFR mutations at exon 19/21 sites showed higher mutation rates in moderately differentiated adenocarcinomas, particularly in lepidic and acinar subtypes, and low mutation rates in mucinous subtypes. This evidence concerns the gene EGFR and adenocarcinoma.